Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 does not improve peripheral insulin sensitivity in statin-treated men and women: the LIFESTAT study.
Appl Physiol Nutr Metab. 2019 May; 44(5):485-492.AP

Abstract

Simvastatin is a cholesterol-lowering drug that is prescribed to lower the risk of cardiovascular disease following high levels of blood cholesterol. There is a possible risk of new-onset diabetes mellitus with statin treatment but the mechanisms behind are unknown. Coenzyme Q10 (CoQ10) supplementation has been found to improve glucose homeostasis in various patient populations and may increase muscle glucose transporter type 4 content. Our aim was to investigate if 8 weeks of CoQ10 supplementation can improve glucose homeostasis in simvastatin-treated subjects. Thirty-five men and women in treatment with a minimum of 40 mg of simvastatin daily were randomized to receive either 2 × 200 mg/day of CoQ10 supplementation or placebo for 8 weeks. Glucose homeostasis was investigated with fasting blood samples, oral glucose tolerance test (OGTT) and intravenous glucose tolerance test. Insulin sensitivity was assessed with the hyperinsulinemic-euglycemic clamp. Different indices were calculated from fasting samples and OGTT as secondary measures of insulin sensitivity. A muscle biopsy was obtained from the vastus lateralis muscle for muscle protein analyzes. There were no changes in body composition, fasting plasma insulin, fasting plasma glucose, or 3-h glucose with intervention, but glycated hemoglobin decreased with time. Glucose homeostasis measured as the area under the curve for glucose, insulin, and C-peptide during OGTT was unchanged after intervention. Insulin secretory capacity was also unaltered after CoQ10 supplementation. Insulin sensitivity was unchanged but hepatic insulin sensitivity increased. No changes in muscle GLUT4 content was observed after intervention. CoQ10 supplementation does not change muscle GLUT4 content, insulin sensitivity, or secretory capacity, but hepatic insulin sensitivity may improve.

Authors+Show Affiliations

a Xlab, Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.a Xlab, Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.a Xlab, Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.a Xlab, Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.a Xlab, Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.a Xlab, Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.a Xlab, Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark. b Department of Geriatrics, Bispebjerg University Hospital, 2400 Copenhagen, Denmark.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

30273493

Citation

Kuhlman, Anja Birk, et al. "Coenzyme Q10 Does Not Improve Peripheral Insulin Sensitivity in Statin-treated Men and Women: the LIFESTAT Study." Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme, vol. 44, no. 5, 2019, pp. 485-492.
Kuhlman AB, Morville T, Dohlmann TL, et al. Coenzyme Q10 does not improve peripheral insulin sensitivity in statin-treated men and women: the LIFESTAT study. Appl Physiol Nutr Metab. 2019;44(5):485-492.
Kuhlman, A. B., Morville, T., Dohlmann, T. L., Hansen, M., Kelly, B., Helge, J. W., & Dela, F. (2019). Coenzyme Q10 does not improve peripheral insulin sensitivity in statin-treated men and women: the LIFESTAT study. Applied Physiology, Nutrition, and Metabolism = Physiologie Appliquee, Nutrition Et Metabolisme, 44(5), 485-492. https://doi.org/10.1139/apnm-2018-0488
Kuhlman AB, et al. Coenzyme Q10 Does Not Improve Peripheral Insulin Sensitivity in Statin-treated Men and Women: the LIFESTAT Study. Appl Physiol Nutr Metab. 2019;44(5):485-492. PubMed PMID: 30273493.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coenzyme Q10 does not improve peripheral insulin sensitivity in statin-treated men and women: the LIFESTAT study. AU - Kuhlman,Anja Birk, AU - Morville,Thomas, AU - Dohlmann,Tine Lovsø, AU - Hansen,Maria, AU - Kelly,Bo, AU - Helge,Jørn Wulff, AU - Dela,Flemming, Y1 - 2018/10/01/ PY - 2018/10/3/pubmed PY - 2019/9/7/medline PY - 2018/10/2/entrez KW - CoQ10 supplementation KW - cardiovascular disease KW - cholesterol-lowering therapy KW - diabète sucré d’apparition récente KW - hypercholesterolemia KW - hypercholestérolémie KW - lipides KW - lipids KW - maladie cardiovasculaire KW - new-onset diabetes mellitus KW - statines KW - statins KW - supplémentation en CoQ10 KW - traitement hypocholestérolémiant SP - 485 EP - 492 JF - Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme JO - Appl Physiol Nutr Metab VL - 44 IS - 5 N2 - Simvastatin is a cholesterol-lowering drug that is prescribed to lower the risk of cardiovascular disease following high levels of blood cholesterol. There is a possible risk of new-onset diabetes mellitus with statin treatment but the mechanisms behind are unknown. Coenzyme Q10 (CoQ10) supplementation has been found to improve glucose homeostasis in various patient populations and may increase muscle glucose transporter type 4 content. Our aim was to investigate if 8 weeks of CoQ10 supplementation can improve glucose homeostasis in simvastatin-treated subjects. Thirty-five men and women in treatment with a minimum of 40 mg of simvastatin daily were randomized to receive either 2 × 200 mg/day of CoQ10 supplementation or placebo for 8 weeks. Glucose homeostasis was investigated with fasting blood samples, oral glucose tolerance test (OGTT) and intravenous glucose tolerance test. Insulin sensitivity was assessed with the hyperinsulinemic-euglycemic clamp. Different indices were calculated from fasting samples and OGTT as secondary measures of insulin sensitivity. A muscle biopsy was obtained from the vastus lateralis muscle for muscle protein analyzes. There were no changes in body composition, fasting plasma insulin, fasting plasma glucose, or 3-h glucose with intervention, but glycated hemoglobin decreased with time. Glucose homeostasis measured as the area under the curve for glucose, insulin, and C-peptide during OGTT was unchanged after intervention. Insulin secretory capacity was also unaltered after CoQ10 supplementation. Insulin sensitivity was unchanged but hepatic insulin sensitivity increased. No changes in muscle GLUT4 content was observed after intervention. CoQ10 supplementation does not change muscle GLUT4 content, insulin sensitivity, or secretory capacity, but hepatic insulin sensitivity may improve. SN - 1715-5320 UR - https://www.unboundmedicine.com/medline/citation/30273493/Coenzyme_Q10_does_not_improve_peripheral_insulin_sensitivity_in_statin_treated_men_and_women:_the_LIFESTAT_study_ L2 - http://www.nrcresearchpress.com/doi/full/10.1139/apnm-2018-0488?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -